Dana-Farber Cancer Institute: Endometrial Neoplasms trials

The registry lists 13 Endometrial Neoplasms studies with Dana-Farber Cancer Institute as lead sponsor. 6 are open to participants now and 3 have results posted.

Phase 1 3Phase 2 7No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialNot yet recruitingNCT07832227Phase 2
• Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic OriginRecruitingNCT06677190Phase 2
• ALPINE: Maintenance Letrozole/AbemaciclibRecruitingNCT06366347Phase 2
• Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving ChemotherapyRecruitingNCT04997096Not applicable
• Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial NeoplasiaRecruitingNCT04839614Not applicable
• RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial CancerRecruitingNCT03675893Phase 2
• A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)Active, not recruitingNCT03835819Phase 2Results posted
• Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial CancerActive, not recruitingNCT02912572Phase 2Results posted
• Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological CancersCompletedNCT00545792Phase 2Results posted
• Durvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerTerminatedNCT03277482Phase 1
• Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsSuspendedNCT03065062Phase 1
• Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer PatientsCompletedNCT00268918Phase 1
• Dosimetric Analysis of Vaginal Cuff Brachytherapy in Endometrial CarcinomaCompletedNCT00165126